1
|
Hampton CE, Kleine SA, Smith JS, Mulon PY, Smith CK, Shanks GA, Vanecek LR, Seddighi R, Cox S. Pharmacokinetics of oral clonazepam in growing commercial pigs (Sus scrofa domestica). J Vet Pharmacol Ther 2024. [PMID: 38706125 DOI: 10.1111/jvp.13451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2024] [Revised: 03/11/2024] [Accepted: 04/20/2024] [Indexed: 05/07/2024]
Abstract
Clonazepam causes sedation and psychomotor impairment in people. Due to similarities between people and swine in response to benzodiazepines, clonazepam may represent a viable option to produce mild-to-moderate tranquillization in pigs. The objective of this study was to determine the pharmacokinetic profile of a single oral dose (0.5 mg/kg) of clonazepam in eight healthy, growing commercial cross pigs. Serial plasma samples were collected at baseline and up to 96 h after administration. Plasma concentrations were quantified using reverse-phase high-performance liquid chromatography, and compartment models were fit to time-concentration data. A one-compartment first-order model best fits the data. Maximum plasma concentration was 99.5 ng/mL, and time to maximum concentration was 3.4 h. Elimination half-life was 7.3 h, mean residence time 7.4 h, and apparent volume of distribution 5.7 L/kg. Achieved plasma concentrations exceeded those associated with psychomotor impairment in people although pharmacodynamic effects have not been investigated in pigs. A simulated oral regimen consisting of 0.35 mg/kg administered every 8 h to pigs would achieve plasma concentrations above 32 ng/mL which are shown to produce psychomotor impairment in people. Further studies to test the clinical efficacy of these dosages in commercial and miniature pigs are warranted.
Collapse
Affiliation(s)
- Chiara E Hampton
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA
| | - Stephanie A Kleine
- Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA
| | - Joe S Smith
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA
| | - Pierre-Yves Mulon
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA
| | - Christopher K Smith
- Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA
| | - Gregory A Shanks
- College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA
| | | | - Reza Seddighi
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA
| | - Sherry Cox
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA
| |
Collapse
|
2
|
Davyson E, Shen X, Huider F, Adams M, Borges K, McCartney D, Barker L, Van Dongen J, Boomsma D, Weihs A, Grabe H, Kühn L, Teumer A, Völzke H, Zhu T, Kaprio J, Ollikainen M, David FS, Meinert S, Stein F, Forstner AJ, Dannlowski U, Kircher T, Tapuc A, Czamara D, Binder EB, Brückl T, Kwong A, Yousefi P, Wong C, Arseneault L, Fisher HL, Mill J, Cox S, Redmond P, Russ TC, van den Oord E, Aberg KA, Penninx B, Marioni RE, Wray NR, McIntosh AM. Antidepressant Exposure and DNA Methylation: Insights from a Methylome-Wide Association Study. medRxiv 2024:2024.05.01.24306640. [PMID: 38746357 PMCID: PMC11092700 DOI: 10.1101/2024.05.01.24306640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/16/2024]
Abstract
Importance Understanding antidepressant mechanisms could help design more effective and tolerated treatments. Objective Identify DNA methylation (DNAm) changes associated with antidepressant exposure. Design Case-control methylome-wide association studies (MWAS) of antidepressant exposure were performed from blood samples collected between 2006-2011 in Generation Scotland (GS). The summary statistics were tested for enrichment in specific tissues, gene ontologies and an independent MWAS in the Netherlands Study of Depression and Anxiety (NESDA). A methylation profile score (MPS) was derived and tested for its association with antidepressant exposure in eight independent cohorts, alongside prospective data from GS. Setting Cohorts; GS, NESDA, FTC, SHIP-Trend, FOR2107, LBC1936, MARS-UniDep, ALSPAC, E-Risk, and NTR. Participants Participants with DNAm data and self-report/prescription derived antidepressant exposure. Main Outcomes and Measures Whole-blood DNAm levels were assayed by the EPIC/450K Illumina array (9 studies, N exposed = 661, N unexposed = 9,575) alongside MBD-Seq in NESDA (N exposed = 398, N unexposed = 414). Antidepressant exposure was measured by self- report and/or antidepressant prescriptions. Results The self-report MWAS (N = 16,536, N exposed = 1,508, mean age = 48, 59% female) and the prescription-derived MWAS (N = 7,951, N exposed = 861, mean age = 47, 59% female), found hypermethylation at seven and four DNAm sites (p < 9.42x10 -8 ), respectively. The top locus was cg26277237 ( KANK1, p self-report = 9.3x10 -13 , p prescription = 6.1x10 -3 ). The self-report MWAS found a differentially methylated region, mapping to DGUOK-AS1 ( p adj = 5.0x10 -3 ) alongside significant enrichment for genes expressed in the amygdala, the "synaptic vesicle membrane" gene ontology and the top 1% of CpGs from the NESDA MWAS (OR = 1.39, p < 0.042). The MPS was associated with antidepressant exposure in meta-analysed data from external cohorts (N studies = 9, N = 10,236, N exposed = 661, f3 = 0.196, p < 1x10 -4 ). Conclusions and Relevance Antidepressant exposure is associated with changes in DNAm across different cohorts. Further investigation into these changes could inform on new targets for antidepressant treatments. 3 Key Points Question: Is antidepressant exposure associated with differential whole blood DNA methylation?Findings: In this methylome-wide association study of 16,536 adults across Scotland, antidepressant exposure was significantly associated with hypermethylation at CpGs mapping to KANK1 and DGUOK-AS1. A methylation profile score trained on this sample was significantly associated with antidepressant exposure (pooled f3 [95%CI]=0.196 [0.105, 0.288], p < 1x10 -4 ) in a meta-analysis of external datasets. Meaning: Antidepressant exposure is associated with hypermethylation at KANK1 and DGUOK-AS1 , which have roles in mitochondrial metabolism and neurite outgrowth. If replicated in future studies, targeting these genes could inform the design of more effective and better tolerated treatments for depression.
Collapse
|
3
|
Hiebert K, Cox S, Hawkins S. Subcutaneous administration of ceftazidime at 20 and 40 mg/kg produces theoretically therapeutic plasma concentrations for at least 120 hours in red-eared sliders (Trachemys scripta elegans). Am J Vet Res 2024; 85:ajvr.23.11.0265. [PMID: 38412607 DOI: 10.2460/ajvr.23.11.0265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2023] [Accepted: 02/10/2024] [Indexed: 02/29/2024]
Abstract
OBJECTIVE To evaluate and compare the pharmacokinetic parameters of SC ceftazidime administered at 20 and 40 mg/kg to red-eared sliders. ANIMALS 8 adult red-eared sliders (Trachemys scripta elegans). METHODS In a sequential, 2-period study with a 3-week washout period between treatments, ceftazidime was administered SC to turtles at 20 and 40 mg/kg. Blood samples were collected from the subcarapacial sinus at 0, 24, 48, 72, 96, and 120 hours after ceftazidime administration. Plasma ceftazidime concentrations were quantified using reversed-phase HPLC. RESULTS Mean plasma half-life after 20- and 40-mg/kg dosing was 39.75 ± 8.0 hours and 33.03 ± 6.56 hours, respectively. Mean maximum plasma concentration after 20- and 40-mg/kg dosing was 71.0 ± 15.93 µg/mL and 120.0 ± 30.62 µg/mL, respectively. Mean plasma ceftazidime concentrations remained ≥ 8 µg/mL, the theoretical MIC for various reptile pathogens for all time points. CLINICAL RELEVANCE Results indicate that ceftazidime dosed at either 20 or 40 mg/kg produces plasma concentrations exceeding the theoretical MIC of various reptile pathogens for at least 120 hours. An ideal dosing interval could not be determined, as all plasma concentrations remained above the threshold of interest for all time points. Follow-up studies should focus on establishing a dosing interval and more rigorous monitoring for potential adverse effects.
Collapse
Affiliation(s)
- Kara Hiebert
- Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI
| | - Sherry Cox
- Department of Comparative Medicine, College of Veterinary Medicine, University of Tennessee, Knoxville, TN
| | - Shawna Hawkins
- Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI
| |
Collapse
|
4
|
Yuschenkoff D, Cole GA, D'Agostino J, Lock B, Cox S, Sladky KK. PHARMACOKINETICS OF TRAMADOL AND O-DESMETHYLTRAMADOL IN GIANT TORTOISES ( CHELONOIDIS VANDENBURGHI, CHELONOIDIS VICINA). J Zoo Wildl Med 2024; 55:86-91. [PMID: 38453491 DOI: 10.1638/2023-0062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/12/2023] [Indexed: 03/09/2024] Open
Abstract
The objective of this study was to determine the pharmacokinetics of two orally administered doses of tramadol (1 mg/kg and 5 mg/kg) and its metabolite, O-desmethyltramadol (M1) in giant tortoises (Chelonoidis vandenburghi, Chelonoidis vicina). Eleven giant tortoises (C. vandenburghi, C. vicina) received two randomly assigned, oral doses of tramadol (either 1 mg/kg or 5 mg/kg), with a washout period of 3 wk between each dose. The half-life (t½) of orally administered tramadol at 1 mg/kg and 5 mg/kg was 11.9 ± 4.6 h and 13.2 ± 6.1 h, respectively. After oral administration of tramadol at 1 mg/kg and 5 mg/kg, the maximum concentration (Cmax) was 125 ± 69 ng/ml and 518 ± 411 ng/ml, respectively. There were not enough data points to determine pharmacokinetic (PK) parameters for the M1 metabolite from either dose. Tramadol administered orally to giant tortoises at both doses provided measurable plasma concentrations of tramadol for approximately 48 h with occasional transient sedation. Oral tramadol at 5 mg/kg, on average, achieves concentrations of >100 ng/ml, the reported human therapeutic threshold, for 24 h. Based on the low levels of M1 seen in this study, M1 may not be a major metabolite in this taxon.
Collapse
Affiliation(s)
| | | | | | - Brad Lock
- Oklahoma City Zoo, Oklahoma City, OK 73111, USA
| | - Sherry Cox
- The University of Tennessee, Knoxville, Knoxville, TN 37996, USA
| | - Kurt K Sladky
- Department of Surgical Sciences, University of Wisconsin-Madison School of Veterinary Medicine, Madison, WI 53706, USA
| |
Collapse
|
5
|
Walter B, Johnson S, Sladky K, Cox S, Thurber M. SERUM FENTANYL CONCENTRATIONS AND BEHAVIOR ASSOCIATED WITH TRANSDERMAL FENTANYL APPLICATION ON HEALTHY CORN SNAKES ( PANTHEROPHIS GUTTATUS). J Zoo Wildl Med 2024; 54:738-745. [PMID: 38251997 DOI: 10.1638/2022-0162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/06/2023] [Indexed: 01/23/2024] Open
Abstract
Snakes are common household pets and frequently managed in zoos. Geriatric snakes commonly develop osteoarthritis, leading to a declining quality of life that often results in euthanasia. Anecdotally, the application of transdermal fentanyl patches (TFP) appears to contribute to clinical improvement, including increased activity level, in osteoarthritic snakes presumed to be in pain. This study evaluated serum fentanyl concentrations over time and the effects of TFP on the normal behavior of healthy, captive, adult corn snakes (Pantherophis guttatus) using constant video monitoring. Serum fentanyl concentrations were evaluated over 4 wk during 12.5 µg/h TFP application, and the results demonstrated long-lasting (>4 wk) serum concentrations that were consistent with analgesic efficacy in mammalian species during TFP application. At 4 wk of TFP application, mean serum fentanyl concentrations were 11.5 ± 5.5 ng/ml. Snakes were videotaped for 1 wk prior to and 2 wk after 12.5 µg/h TFP application, and behavior was evaluated by an ethogram. Behavioral changes associated with TFP application included decreased mean time spent active, decreased mean number of climbs, and decreased mean number of water visits; feeding behavior was unchanged. Overall, these results suggest that TFP application may provide safe, clinically effective analgesia in healthy corn snakes for at least 4 wk without inducing deleterious side effects, and may therefore be appropriate analgesia for management of osteoarthritic snakes.
Collapse
Affiliation(s)
- Benjamin Walter
- Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA
| | - Stephen Johnson
- Departments of Comparative Biosciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA
| | - Kurt Sladky
- Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA
| | - Sherry Cox
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN 37996, USA
| | - Mary Thurber
- Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA,
| |
Collapse
|
6
|
Haynes E, Stanford K, Cox S, Vivirito K, Durante K, Wright A, Gramhofer M, Pohly A, Gartlan B, Fredrickson K, Allender MC. CONTROLLED CLINICAL TRIAL USING TERBINAFINE NEBULIZATION TO TREAT WILD LAKE ERIE WATERSNAKES ( NERODIA SIPEDON INSULARUM) WITH OPHIDIOMYCOSIS. J Zoo Wildl Med 2024; 54:746-756. [PMID: 38251998 DOI: 10.1638/2023-0050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/01/2023] [Indexed: 01/23/2024] Open
Abstract
Ophidiomycosis (snake fungal disease) is an important infectious disease caused by the fungus Ophidiomyces ophidiicola. To mitigate the disease's impact on individual snakes, a controlled clinical trial was conducted using terbinafine nebulization to treat snakes with ophidiomycosis. Fifty-three wild-caught Lake Erie watersnakes (Nerodia sipedon insularum) with apparent ophidiomycosis (skin lesions present, qPCR positive for O. ophidiicola) were divided into treatment and control groups: treatment snakes were nebulized with a 2 mg/ml terbinafine solution for 30 min daily for 30 d; control snakes received nebulization with 0.9% saline or no nebulization. Weekly physical exams were conducted to assign disease severity scores based on the number, type, location, and size of lesions, and qPCR was repeated after each 30-d course of treatment. Persistently qPCR-positive snakes received multiple nebulization courses. Terbinafine nebulization showed mixed results as a treatment for ophidiomycosis: 29.2% of animals treated with terbinafine showed molecular resolution of external disease, based on antemortem swabbing, following 3-6 mon of daily nebulization; this was significantly more than with saline nebulization (5%), but molecular resolution also occurred in 11.1% of snakes that received no treatment. Terbinafine nebulization did not significantly decrease clinical disease, as measured by disease severity scores. Evaluating molecular response to treatment using fungal quantities, terbinafine nebulization significantly reduced fungal quantity after three or more courses of treatment. These results indicate that, although terbinafine nebulization is a promising treatment for ophidiomycosis, snakes may require multiple nebulization courses and disease may not always resolve completely, despite treatment. This treatment may be most useful in snakes from managed populations that can be treated for several months, rather than wild snakes who are not releasable after multiple months in captivity.
Collapse
Affiliation(s)
- Ellen Haynes
- Wildlife Epidemiology Laboratory, University of Illinois Urbana-Champaign, Urbana, IL 61802, USA,
| | - Kristin Stanford
- Franz Theodore Stone Laboratory, The Ohio State University, OH 43456, USA
| | - Sherry Cox
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37996, USA
| | - Kathryn Vivirito
- Wildlife Epidemiology Laboratory, University of Illinois Urbana-Champaign, Urbana, IL 61802, USA
| | - Kennymac Durante
- Wildlife Epidemiology Laboratory, University of Illinois Urbana-Champaign, Urbana, IL 61802, USA
| | - Allison Wright
- Wildlife Epidemiology Laboratory, University of Illinois Urbana-Champaign, Urbana, IL 61802, USA
| | - Megan Gramhofer
- Wildlife Epidemiology Laboratory, University of Illinois Urbana-Champaign, Urbana, IL 61802, USA
| | - Andrea Pohly
- University of Illinois Veterinary Diagnostic Laboratory, Urbana, IL 61802, USA
| | - Brina Gartlan
- Wildlife Epidemiology Laboratory, University of Illinois Urbana-Champaign, Urbana, IL 61802, USA
| | - Kelcie Fredrickson
- Wildlife Epidemiology Laboratory, University of Illinois Urbana-Champaign, Urbana, IL 61802, USA
| | - Matthew C Allender
- Wildlife Epidemiology Laboratory, University of Illinois Urbana-Champaign, Urbana, IL 61802, USA
- Chicago Zoological Society, Brookfield Zoo, Brookfield, IL 60513, USA
| |
Collapse
|
7
|
Helbrow J, Graby J, Lewis G, Cox S, Nicholas O, Radhakrishna G, Crosby T, Gwynne S. Dose Escalation in Esophageal Cancer: Comparing Pre-Accrual and On-Trial Target Volume Delineation in the UK SCOPE2 Trial. Int J Radiat Oncol Biol Phys 2023; 117:e301-e302. [PMID: 37785101 DOI: 10.1016/j.ijrobp.2023.06.2318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The ongoing UK SCOPE2 trial evaluates radiotherapy (RT) dose escalation and PET-guided systemic therapy in esophageal cancer, and has an accompanying RT trials quality assurance (RTTQA) program, evolved through the preceding SCOPE trials. We compare pre-accrual with on-trial individual case review (ICR) target volume delineation (TVD). MATERIALS/METHODS Prior to recruitment, centers were required to undertake TVD exercises using 3D/4D DICOM datasets with relevant clinical details and a RT planning guidance document (RPGD) provided. Contours were then compared against the RTTQA team-defined gold standard. Exceptions were those who had satisfied QA requirements for a previous esophageal RT trial (NeoSCOPE). For ICRs, prospective reviews (prior RT start, PRs) were undertaken for each center's first submission, plus high-dose cases submitted pending formal safety review. Additional PRs were undertaken at the RTTQA team's discretion. Timely retrospective reviews (within 2 weeks of RT start, TRR) were also undertaken for a random 10% sample. TVDs were assessed for compliance using predefined criteria and the RPGD. Resubmission was requested at reviewer's discretion, usually due to unacceptable variation (UV) from protocol. Clarification was sought before contour approval/resubmission request if appropriate. Review outcomes were then evaluated. PTV6000 was new to SCOPE2, along with a greater emphasis on use of 4DCT than in prior SCOPE trials. RESULTS A total of 85 pre-accrual cases from 33 UK centers were reviewed, of which 20 (24%) were resubmissions, and 50 (59%) were accepted. 99 TVD UVs were observed in 49 cases, most commonly in CTVB (42/99, 42%), which included editing for normal structures and elective lymph node regions, followed by ITV (4D cases only, 14/52, 27%) and PTV6000 (13/99, 13%). 121 ICRs from 31 UK centers were available for review. 87 (72%) were PRs and 34 (28%) TRRs. 43 (36%) completed the relevant SCOPE2 exercise. 19 (16%) were resubmissions, and 82 (68%) were accepted. 72 UVs were observed in 45 ICRs; again, most commonly in CTVB (34/72, 48%), PTV6000 (high dose arm only, 11/46, 24%) and ITV (4D only, 5/26, 19%). Of the 45 cases where a UV was recorded, 16 (36%) had completed the relevant SCOPE2 pre-accrual. Comparing area of UV on SCOPE2 pre-accrual cases and ICRs, 3 (19%) contours contained the same (2 = CTVB, 1 = PTV6000), 5 (31%) contained different and 8 (50%) had no UVs at pre-accrual. The rate of UV was significantly lower for ICR than for pre-accrual submissions (0.60 and 1.16 respectively, p = 0.001). CONCLUSION Significantly fewer UVs in ICR compared with pre-accrual supports a robust, educational RTTQA program through national collaboration and evolving trial series. CTVB, along with newer volumes of ITV and PTV6000, were recurring UV domains and should inform RPGD development and RTTQA for ongoing recruitment and future trials.
Collapse
Affiliation(s)
- J Helbrow
- South West Wales Cancer Centre, Swansea, United Kingdom
| | - J Graby
- University of Bath, Bath, United Kingdom
| | - G Lewis
- Velindre Cancer Centre, Cardiff, United Kingdom
| | - S Cox
- Velindre Cancer Centre, Cardiff, United Kingdom
| | - O Nicholas
- South West Wales Cancer Centre, Swansea, United Kingdom; Swansea University, Swansea, United Kingdom
| | | | - T Crosby
- Velindre Cancer Centre, Cardiff, United Kingdom
| | - S Gwynne
- South West Wales Cancer Centre, Swansea, United Kingdom; Swansea University, Swansea, United Kingdom
| |
Collapse
|
8
|
Shuttleworth JR, Behrens KN, Biggo MR, Horne RL, Cox S, Lakritz J, Tinga S. Effect of storage duration on carprofen concentration measurements in dog plasma. Vet Med Sci 2023; 9:2022-2025. [PMID: 37471576 PMCID: PMC10508557 DOI: 10.1002/vms3.1215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2022] [Revised: 03/20/2023] [Accepted: 07/06/2023] [Indexed: 07/22/2023] Open
Abstract
BACKGROUND Storage of samples may be necessary prior to testing drug levels in certain study designs; however, the effect of storage duration on measured drug levels is not known for all drugs. OBJECTIVES The objective of this study was to evaluate the stability of carprofen in canine plasma when stored at -80°C for 6 months. METHODS Six healthy dogs were enrolled (1-10 years old, 17-35 kg) and received compounded carprofen at 2.2 mg/kg orally every 12 h for 2 days. On the third day, blood was collected immediately before the morning dose (trough), then 1 and 6 h after the dose (sampling timepoint). Whole blood was immediately centrifuged, and plasma was stored at -80°C. Plasma carprofen concentration was measured at day 2, week 2 and then monthly for 6 months using reversed-phase high-performance liquid chromatography. The measured carprofen concentrations were analysed statistically using a linear mixed effects model. RESULTS There was no effect of storage time over 6 months (p = 0.891) on measured carprofen levels. Although there was an effect of sampling timepoint (0, 1 and 6 h) (p < 0.001), the interaction between storage timepoint and sampling timepoint was not statistically significant (p = 1). CONCLUSIONS Carprofen-laden canine plasma samples can be stored for up to 6 months before analysis with no degradation in carprofen concentrations expected.
Collapse
Affiliation(s)
| | | | - Morgan R. Biggo
- The Ohio State University College of Veterinary MedicineColumbusOhioUSA
| | - Rikki L. Horne
- The Ohio State University College of Veterinary MedicineColumbusOhioUSA
| | - Sherry Cox
- University of Tennessee College of Veterinary MedicineKnoxvilleTennesseeUSA
| | - Jeffrey Lakritz
- The Ohio State University College of Veterinary MedicineColumbusOhioUSA
| | - Selena Tinga
- The Ohio State University College of Veterinary MedicineColumbusOhioUSA
- Present address:
Cornell University College of Veterinary MedicineIthacaNYUSA
| |
Collapse
|
9
|
Kleine S, Hampton CE, Smith C, Bussieres G, Mulon PY, Seddighi R, Cox S, Smith J. Pharmacokinetics of a single oral dose of grapiprant in juvenile pigs (Sus scrofa domestica). J Vet Pharmacol Ther 2023; 46:269-275. [PMID: 37493273 DOI: 10.1111/jvp.13402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Revised: 06/07/2023] [Accepted: 06/20/2023] [Indexed: 07/27/2023]
Abstract
Both pet and research pigs can suffer from some degree of pain from surgery, injuries, or osteoarthritis (OA). Despite this, there is a paucity of data on safe and effective analgesia agents in pigs. Grapiprant is an EP4 antagonist that blocks the action of the pro-inflammatory prostanoid, PGE2 . It has shown efficacy in attenuating pain associated with ovariohysterectomy and OA in dogs. However, there are no data regarding grapiprant in pigs. Therefore, the pharmacokinetic profile of orally administered grapiprant to juvenile pigs (Sus scrofa domestica) was evaluated in this study. Seven juvenile pigs received 12 mg/kg grapiprant orally. Blood was collected from an indwelling jugular catheter using the push-pull method at set timepoints up to 48 hours. Sample analysis was performed with high-performance liquid chromatography. Mean grapiprant plasma concentration was 164.3 ± 104.7 ng/mL which occurred at 0.8 ± 0.3 h. This study demonstrated that grapiprant concentrations consistent with analgesia in dogs were reached at this dosage in pigs. Further studies are needed to evaluate the efficacy of grapiprant in pigs.
Collapse
Affiliation(s)
- Stephanie Kleine
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA
| | - Chiara E Hampton
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA
| | - Christopher Smith
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA
| | - Genevieve Bussieres
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA
| | - Pierre-Yves Mulon
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA
| | - Reza Seddighi
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA
| | - Sherry Cox
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA
| | - Joe Smith
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA
| |
Collapse
|
10
|
Minich DJ, Fayette MA, Cox S. Pharmacokinetics of robenacoxib after a single intramuscular dose in smooth dogfish (Mustelus canis). Am J Vet Res 2023; 84:1-4. [PMID: 37541671 DOI: 10.2460/ajvr.23.06.0130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Accepted: 07/31/2023] [Indexed: 08/06/2023]
Abstract
OBJECTIVE To determine the pharmacokinetics of robenacoxib after a single intramuscular dose (4.0 mg/kg) in smooth dogfish (Mustelus canis). ANIMALS 8 healthy adult male smooth dogfish in human care within the same habitat. METHODS All sharks received a single intramuscular dose of robenacoxib (4.0 mg/kg) in the right caudolateral epaxial musculature. Blood samples were collected under manual restraint from the ventral tail vessel at 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, and 24 hours after drug administration. Plasma drug concentrations were determined by HPLC followed by noncompartmental pharmacokinetic analysis of the data. RESULTS A maximum plasma concentration of 1.24 µg/mL was reached at a mean time of 30 minutes following robenacoxib administration with a plasma elimination half-life of 3.79 hours. Plasma concentrations did not fall below the lower limit of quantification (0.1 µg/mL) at the time points sampled in this study. CLINICAL RELEVANCE Intramuscular administration of a single dose (4.0 mg/kg) of robenacoxib in smooth dogfish resulted in rapid absorption to a maximum concentration at approximately 30 minutes after administration and persisted above levels considered to be therapeutic in domestic species for at least 8 hours.
Collapse
Affiliation(s)
| | | | - Sherry Cox
- University of Tennessee, College of Veterinary Medicine, Knoxville, TN
| |
Collapse
|
11
|
Crichton J, Cox S, Tong C, Leow P, Field X, Welsh F. Observation versus intervention for incidental common bile duct stones at intraoperative cholangiogram: a systematic review. ANZ J Surg 2023; 93:1839-1846. [PMID: 37381094 DOI: 10.1111/ans.18581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2023] [Revised: 06/15/2023] [Accepted: 06/20/2023] [Indexed: 06/30/2023]
Abstract
BACKGROUND The natural history of incidental common bile duct stones (CBDS) is poorly understood. Current evidence is conflicting, with several studies suggesting the majority may pass spontaneously. Despite this, guidelines recommend routine removal even if asymptomatic. This study aimed to systematically review the outcomes of expectant management for CBDS detected on operative cholangiography during cholecystectomy. METHODS MEDLINE, Embase and CINAHL databases were systematically searched. Participants were adult patients with CBDS identified by intraoperative cholangiography. Intervention was regarded as any perioperative effort to remove common bile duct stones, including endoscopic retrograde cholangiopancreatography (ERCP), laparoscopic and open bile duct exploration. This was compared to observation. Outcomes of interest included rates of spontaneous stone passage, success of duct clearance and complications. Risk of bias was assessed using the ROBINS-I tool. RESULTS Eight studies were included. All studies were non-randomized, heterogeneous and at serious risk of bias. In patients observed after a positive IOC, 20.9% went on to have symptomatic retained stones. In patients directed to ERCP for positive IOC, persistent CBDS were found in 50.6%. Spontaneous passage was not associated with stone size. Meta-analysis is dominated by the results from one large database, which recommends intervention for incidental stones, despite low rates of persistent stones seen at postoperative ERCP. CONCLUSIONS Further evidence is required before a definitive recommendation on observation can be made. There is some evidence that asymptomatic stones may be safely observed. In clinical scenarios where the risks of biliary intervention are considered high, a conservative strategy could be more widely considered.
Collapse
Affiliation(s)
- J Crichton
- Department of General Surgery, Te Whatu Ora Waitaha Canterbury, Christchurch Hospital, Christchurch, New Zealand
- Department of General Surgery, Te Whatu Ora Waikato, Waikato Hospital, Hamilton, New Zealand
| | - S Cox
- Department of General Surgery, Te Whatu Ora Waikato, Waikato Hospital, Hamilton, New Zealand
| | - C Tong
- Department of General Surgery, Te Whatu Ora Waikato, Waikato Hospital, Hamilton, New Zealand
| | - P Leow
- Department of General Surgery, Te Whatu Ora Waikato, Waikato Hospital, Hamilton, New Zealand
| | - X Field
- Department of General Surgery, Te Whatu Ora Waikato, Waikato Hospital, Hamilton, New Zealand
| | - F Welsh
- Department of General Surgery, Te Whatu Ora Waikato, Waikato Hospital, Hamilton, New Zealand
| |
Collapse
|
12
|
Smith JS, Gebert J, Bennett K, Ebner LS, Flynn R, Mulon PY, Harvill L, Escher OG, Kreuder AJ, Bergman J, Cox S. The pharmacokinetics and pharmacodynamics of esomeprazole in sheep after intravenous dosing. Front Vet Sci 2023; 10:1172023. [PMID: 37215479 PMCID: PMC10196163 DOI: 10.3389/fvets.2023.1172023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Accepted: 04/04/2023] [Indexed: 05/24/2023] Open
Abstract
Abomasal (gastric) ulceration is a morbidity in sheep, and currently, there is a paucity of pharmacokinetic and pharmacodynamic data for gastroprotectant drugs reported for this species. The proton pump inhibitor esomeprazole has been used in small animal and human patients for gastroprotection via increasing the gastric pH. The objective of this study was to report the pharmacokinetic parameters and pharmacodynamic effect of esomeprazole in sheep after single intravenous dosing. Four healthy adult Southdown cross ewes had blood collected over a 24 h time period after single intravenous dosing of esomeprazole at 1.0 mg/kg. Abomasal fluid was sampled over 24 h before and after esomeprazole administration. Plasma samples were analyzed for concentrations of esomeprazole and the esomeprazole metabolite, esomeprazole sulfone by high performance liquid chromatography. Pharmacokinetic and pharmacodynamic data were evaluated with specialized software. Esomeprazole was rapidly eliminated after IV administration. Elimination half-life, area under the curve, initial concentration (C0), and clearance were 0.2 h, 1,197 h*ng/mL, 4,321 ng/mL, and 0.83 mL/h/kg, respectively. For the sulfone metabolite elimination half-life, area under the curve and maximum concentration were 0.16 h, 22.5 h*ng/mL, and 65.0 ng/mL, respectively. Abomasal pH was significantly elevated from 1 to 6 h after administration and remained above 4.0 for at least 8 h after administration. No adverse effects were noted in these sheep. Esomeprazole was rapidly eliminated in sheep, similar to goats. Abomasal pH was increased, but future studies will be necessary to develop a clinical management approach to the use of esomeprazole in sheep.
Collapse
Affiliation(s)
- Joe S. Smith
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, United States
- Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA, United States
| | - Jessica Gebert
- Lincoln Memorial University, College of Veterinary Medicine, Harrogate, TN, United States
| | - Kailee Bennett
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, United States
| | - Lisa Sams Ebner
- Lincoln Memorial University, College of Veterinary Medicine, Harrogate, TN, United States
| | - Ryan Flynn
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, United States
| | - Pierre-Yves Mulon
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, United States
| | - Lainey Harvill
- Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, United States
| | - Olivia Grace Escher
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, United States
| | - Amanda Jo Kreuder
- Veterinary Microbiology and Preventative Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, United States
| | - Joan Bergman
- Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, United States
| | - Sherry Cox
- Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, United States
| |
Collapse
|
13
|
Ambar N, Cox S, Hartup BK. PHARMACOKINETICS OF CEFTIOFUR CRYSTALLINE-FREE ACID ADMINISTERED VIA INTRAMUSCULAR INJECTION IN WHOOPING CRANES ( GRUS AMERICANA). J Zoo Wildl Med 2023; 54:1-7. [PMID: 36971622 DOI: 10.1638/2022-0058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/10/2022] [Indexed: 03/29/2023] Open
Abstract
The objective of this study was to evaluate the pharmacokinetic properties of a single dose of ceftiofur crystalline-free acid (CCFA) in whooping cranes (Grus americana). Ceftiofur crystalline-free acid is a long-acting, injectable, third-generation cephalosporin antibiotic drug. A preliminary study evaluated CCFA administered intramuscularly in the pectoral or thigh muscle at 20 or 30 mg/kg IM to a single adult whooping crane for each dose. On the basis of these data, a dose of 30 mg/kg IM of CCFA was administered to five additional whooping cranes, and blood was collected at various time points from 0 to 288 h. Pharmacokinetic parameters for ceftiofur equivalents were determined and reached concentrations above minimum inhibitory concentrations of various bacteria in other avian species (>1 µg/ml) for at least 96 h in all birds, and for 144 h in two birds. From these findings, ceftiofur crystalline-free acid appears to be a long-acting antibiotic option for whooping cranes and may be dosed every 96 h; however, additional multidose studies are needed.
Collapse
Affiliation(s)
- Neta Ambar
- International Crane Foundation, Baraboo, WI 53913, USA, and the School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA,
| | - Sherry Cox
- University of Tennessee College of Veterinary Medicine, Knoxville, TN 37996, USA
| | - Barry K Hartup
- International Crane Foundation, Baraboo, WI 53913, USA, and the School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA
| |
Collapse
|
14
|
Berg CC, Cox S, Mulreany L, Wolf K, Anderson K. PHARMACOKINETICS OF MELOXICAM AFTER SINGLE ORAL AND INTRAMUSCULAR ADMINISTRATION IN CHINA ROCKFISH ( SEBASTES NEBULOSUS). J Zoo Wildl Med 2023; 54:8-15. [PMID: 36971623 DOI: 10.1638/2022-0080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/25/2022] [Indexed: 03/29/2023] Open
Abstract
Fish species are important for various purposes including aquaculture stock and display animals, but there are significant gaps in the medical knowledge regarding pharmacological parameters and effective pain management. Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that has been studied in few teleost species and with several administration routes. However, these species were typically freshwater or euryhaline fish, and evaluation in marine species is lacking. The pharmacokinetic properties of meloxicam were determined in nine adult China rockfish (Sebastes nebulosus), presumed healthy based on physical examination and benign medical histories. Based on a pilot study, China rockfish were given 1 mg/kg meloxicam via IM injection in the epaxial musculature, and, after a 48-h washout period, 1 mg/kg meloxicam was given by PO gavage. Blood samples were collected from the caudal vein at baseline and at nine time intervals over a 48-h time period following administration of meloxicam. Plasma meloxicam concentrations were determined by reverse phase high-performance liquid chromatography, and noncompartmental analysis was performed. The mean peak plasma concentration after IM injection was 4.9 µg/ml, and the mean terminal half-life was 5.0 h. The mean peak plasma concentration after PO administration was 0.07 µg/ml. Based on these findings, IM injected meloxicam reaches plasma levels consistent with therapeutic concentrations in select mammals, and peak levels were maintained for ≤12 h. Single-dose PO administration failed to achieve similar concentrations, and clinical practicality is unknown. Further studies evaluating NSAID multidose regimes and their pharmacodynamic effects may provide additional dosing information.
Collapse
Affiliation(s)
- Colin C Berg
- Point Defiance Zoo & Aquarium, Tacoma, WA 98407, USA,
| | - Sherry Cox
- University of Tennessee College of Veterinary Medicine, Knoxville, TN 37996, USA
| | | | - Karen Wolf
- Point Defiance Zoo & Aquarium, Tacoma, WA 98407, USA
| | | |
Collapse
|
15
|
Olivarez JD, Mulon PY, Ebner LS, Cremerius H, Cantrell C, Rahn R, Soto-Gonzalez W, Bergman J, Cox S, Mochel JP, Kreuder AJ, Smith JS. Pharmacokinetic and pharmacodynamic properties of pantoprazole in calves. Front Vet Sci 2023; 9:1101461. [PMID: 36794231 PMCID: PMC9923100 DOI: 10.3389/fvets.2022.1101461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2022] [Accepted: 12/29/2022] [Indexed: 02/03/2023] Open
Abstract
Introduction Development of abomasal ulceration is a large concern, especially within calves; however, there is a paucity of research into the use of gastro protectants in ruminant species. Proton pump inhibitors, such as pantoprazole, are widely used in humans and companion animals. Their efficacy in ruminant species is undetermined. The objectives of this study were to 1) estimate the plasma pharmacokinetic parameters for pantoprazole in neonatal calves after three days of intravenous (IV) or subcutaneous (SC) administration, and 2) measure the effect pantoprazole had on abomasal pH over the treatment period. Methods Pantoprazole was administered to 6 Holstein-Angus cross bull calves at a dose of 1 mg/kg (IV) or 2 mg/kg (SC), once a day (every 24 h) for three days. Plasma samples were collected over a 72 h period and analyzed via HPLC-UV for determining pantoprazole concentrations. Pharmacokinetic parameters were derived via non-compartmental analysis. Abomasal (n= 8) samples were collected via abomasal cannulas over a 12 h period, per calf per day. Abomasal pH was determined via a bench top pH analyzer. Results Following Day 1 of IV administration, plasma clearance, elimination half-life, and volume of distribution of pantoprazole were estimated at 199.9 mL/kg/h, 1.44 h, and 0.51 L/kg, respectively. On Day 3 of IV administration, the reported values were 192.9 mL/kg/h, 2.52 h, and 1.80 L/kg mL, respectively. Elimination half-life and volume of distribution (V/F) of pantoprazole following SC administration were estimated at 1.81 h and 0.55 L/kg, respectively, on Day 1; and 2.99 h and 2.82 L/kg, respectively, on Day 3. Discussion The reported values for IV administration were similar to those previously reported in calves. SC administration appears to be well absorbed and tolerated. The sulfone metabolite was detectable for 36 h after the last administration for both routes. Abomasal pH was significantly higher than the pre-pantoprazole pH 4, 6, and 8 h after administration in both the IV and SC groups. Further studies of pantoprazole as a treatment/preventative for abomasal ulcers are warranted.
Collapse
Affiliation(s)
- Jeff D. Olivarez
- Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA, United States,*Correspondence: Jeff D. Olivarez ✉
| | - Pierre-Yves Mulon
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Lisa S. Ebner
- College of Veterinary Medicine, Lincoln Memorial University, Harrogate, TN, United States
| | - Haley Cremerius
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Channing Cantrell
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Rebecca Rahn
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Windy Soto-Gonzalez
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Joan Bergman
- Biomedical and Diagnostic Sciences, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Sherry Cox
- Biomedical and Diagnostic Sciences, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Jonathan P. Mochel
- Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, United States
| | - Amanda J. Kreuder
- Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, United States
| | - Joe S. Smith
- Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA, United States,Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States,Joe S. Smith ✉ ;
| |
Collapse
|
16
|
Hyun NP, Olberding JP, De A, Divi S, Liang X, Thomas E, St Pierre R, Steinhardt E, Jorge J, Longo SJ, Cox S, Mendoza E, Sutton GP, Azizi E, Crosby AJ, Bergbreiter S, Wood RJ, Patek SN. Spring and latch dynamics can act as control pathways in ultrafast systems. Bioinspir Biomim 2023; 18:026002. [PMID: 36595244 DOI: 10.1088/1748-3190/acaa7c] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Accepted: 12/09/2022] [Indexed: 06/17/2023]
Abstract
Ultrafast movements propelled by springs and released by latches are thought limited to energetic adjustments prior to movement, and seemingly cannot adjust once movement begins. Even so, across the tree of life, ultrafast organisms navigate dynamic environments and generate a range of movements, suggesting unrecognized capabilities for control. We develop a framework of control pathways leveraging the non-linear dynamics of spring-propelled, latch-released systems. We analytically model spring dynamics and develop reduced-parameter models of latch dynamics to quantify how they can be tuned internally or through changing external environments. Using Lagrangian mechanics, we test feedforward and feedback control implementation via spring and latch dynamics. We establish through empirically-informed modeling that ultrafast movement can be controllably varied during latch release and spring propulsion. A deeper understanding of the interconnection between multiple control pathways, and the tunability of each control pathway, in ultrafast biomechanical systems presented here has the potential to expand the capabilities of synthetic ultra-fast systems and provides a new framework to understand the behaviors of fast organisms subject to perturbations and environmental non-idealities.
Collapse
Affiliation(s)
- N P Hyun
- John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, United States of America
| | - J P Olberding
- Department of Ecology and Evolutionary Biology, University of California Irvine, Irvine, CA 92697, United States of America
| | - A De
- John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, United States of America
| | - S Divi
- Department of Mechanical Engineering, Carnegie Mellon University, Pittsburgh, PA 15213, United States of America
| | - X Liang
- Polymer Science and Engineering Department, University of Massachusetts Amherst, Amherst, MA 01003, United States of America
| | - E Thomas
- Polymer Science and Engineering Department, University of Massachusetts Amherst, Amherst, MA 01003, United States of America
| | - R St Pierre
- Department of Mechanical Engineering, Carnegie Mellon University, Pittsburgh, PA 15213, United States of America
| | - E Steinhardt
- John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, United States of America
| | - J Jorge
- Biology Department, Duke University, Durham, NC 27708, United States of America
| | - S J Longo
- Biology Department, Duke University, Durham, NC 27708, United States of America
| | - S Cox
- Biology Department, Duke University, Durham, NC 27708, United States of America
| | - E Mendoza
- Department of Ecology and Evolutionary Biology, University of California Irvine, Irvine, CA 92697, United States of America
| | - G P Sutton
- School of Life Sciences, University of Lincoln, Lincoln, United Kingdom
| | - E Azizi
- Department of Ecology and Evolutionary Biology, University of California Irvine, Irvine, CA 92697, United States of America
| | - A J Crosby
- Polymer Science and Engineering Department, University of Massachusetts Amherst, Amherst, MA 01003, United States of America
| | - S Bergbreiter
- Department of Mechanical Engineering, Carnegie Mellon University, Pittsburgh, PA 15213, United States of America
| | - R J Wood
- John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, United States of America
| | - S N Patek
- Biology Department, Duke University, Durham, NC 27708, United States of America
| |
Collapse
|
17
|
Fladung R, Smith JS, Hines MT, Soto-Gonzalez WM, Fayne B, Rahn RR, Escher OG, Harvill L, Bergman J, Garcia JD, Kreuder AJ, Cox S. Pharmacokinetics of esomeprazole in goats ( Capra aegagrus hircus) after intravenous and subcutaneous administration. Front Vet Sci 2022; 9:968973. [PMID: 36590808 PMCID: PMC9797722 DOI: 10.3389/fvets.2022.968973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Accepted: 11/09/2022] [Indexed: 12/23/2022] Open
Abstract
Background Stressed and hospitalized goats are at risk of developing abomasal (gastric) ulceration, but there is a paucity of pharmacokinetic studies for proton pump inhibiting drugs, such as, esomeprazole in goats. Objectives The objectives for this study were to estimate plasma pharmacokinetic parameters for esomeprazole in adult goats after intravenous (IV) and subcutaneous (SQ) administration. A secondary objective was to describe the plasma kinetics of the metabolite esomeprazole sulfone after IV and SC administration in goats. Materials and methods Esomeprazole was administered to 5 adult goats in a crossover study at doses of 1 mg/kg IV or 2 mg/kg SC. Plasma samples were collected over 36 h and analyzed via reverse phase HPLC to determine concentrations of esomeprazole and esomeprazole sulfone. Pharmacokinetic parameters were derived via non-compartmental analysis. Results Following IV administration, mean values for plasma clearance (Cl), elimination half-life [T1/2 (λz)], C0, and volume of distribution (V z ) of esomeprazole were estimated at 24.9 mL/min/kg, 6 min, 2.324 μg/mL, and 0.23 L/kg, respectively. After SC administration elimination half-life, maximum concentration (Cmax) and time to maximum concentration (Tmax) of esomeprazole were estimated at 29 min, 1.038 μg/mL, and 22 minutes respectively. Maximum concentrations of the sulfone metabolite were 32 and 18 ng/mL after IV and SC administration. Conclusion Esomeprazole was rapidly eliminated from plasma after both IV and SC injection in goats. The elimination half-life in goats appears to be shorter than reported in dogs, as well as less than that reported for pantoprazole in goats. The sulfone metabolite was detected and also rapidly eliminated from the plasma after both IV and SC administration. Additional pharmacodynamic investigations are needed to determine the efficacy of esomeprazole on abomasal (gastric) acid suppression in goats and could include larger doses or additional routes of administration.
Collapse
Affiliation(s)
- Rachel Fladung
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Joe S. Smith
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States,Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA, United States,*Correspondence: Joe S. Smith ;
| | - Melissa T. Hines
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Windy Michelle Soto-Gonzalez
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Bryanna Fayne
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Rebecca R. Rahn
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Olivia Grace Escher
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Lainey Harvill
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Joan Bergman
- Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Jessica D. Garcia
- Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Amanda Jo Kreuder
- Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, United States
| | - Sherry Cox
- Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| |
Collapse
|
18
|
Cerreta AJ, Reinhart JM, Forsythe LR, O'Connor MR, Tang KN, Cox S, Keller KA. Bioencapsulation is a feasible method of terbinafine administration in Emydomyces testavorans-infected western pond turtles (Actinemys marmorata). Am J Vet Res 2022; 84:ajvr.22.08.0138. [PMID: 36469441 DOI: 10.2460/ajvr.22.08.0138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
OBJECTIVE To evaluate the pharmacokinetics of terbinafine administered to western pond turtles (Actinemys marmorata) via oral gavage and bioencapsulated in earthworms. ANIMALS 7 western pond turtles. PROCEDURES A randomized complete crossover single-dose pharmacokinetic study was performed. Compounded terbinafine (25 mg/mL; 30 mg/kg) was administered through oral gavage (OG) directly into the stomach or bioencapsulated (BEC) into an earthworm vehicle. Blood (0.2 mL) was drawn from the jugular vein at 0, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, and 120 hours after administration. Plasma terbinafine levels were measured using high-performance liquid chromatography. RESULTS Peak plasma terbinafine concentrations of 786.9 ± 911 ng/mL and 1,022.2 ± 911 were measured at 1.8 ± 2.8 and 14.1 ± 12.3 hours after OG and BEC administration, respectively. There was a significant (P = .031) increase in area under the curve with BEC compared to OG. Using steady-state predictions, with once-daily terbinafine administration, 3/7 and 7/7 turtles had plasma concentrations persistently greater than the minimum inhibitory concentration (MIC) for Emydomyces testavorans for the OG and BEC administration routes of administration, respectively. With administration every 48 hours, 3/7 turtles for the OG phase and 6/7 turtles for the BEC phase had concentrations greater than the E. testavorans MIC throughout the entire dosing interval. CLINICAL RELEVANCE Administration of terbinafine (30 mg/kg) every 24 or 48 hours via earthworm bioencapsulation in western pond turtles may be appropriate for the treatment of shell lesions caused by E. testavorans. Clinical studies are needed to assess the efficacy of treatment.
Collapse
Affiliation(s)
- Anthony J Cerreta
- Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois at Champaign-Urbana, Urbana, IL
| | - Jennifer M Reinhart
- Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois at Champaign-Urbana, Urbana, IL
| | - Lauren R Forsythe
- Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois at Champaign-Urbana, Urbana, IL
| | - Matthew R O'Connor
- A. Watson Armour III Center for Animal Health and Welfare, John G. Shedd Aquarium, Chicago, IL
| | - Karisa N Tang
- A. Watson Armour III Center for Animal Health and Welfare, John G. Shedd Aquarium, Chicago, IL
| | - Sherry Cox
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN
| | - Krista A Keller
- Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois at Champaign-Urbana, Urbana, IL
| |
Collapse
|
19
|
Moliner L, Zellweger N, Schmidt S, Waibel C, Froesch P, Häuptle P, Blum V, Holer L, Frueh M, Bhagani S, Gray HL, Cox S, Khalid T, Scott D, Robinson S, Hennah L, Handforth C, Mauti L, Califano R, Rothschild S. 66P Real-world data of first-line chemo-immunotherapy for patients with extensive stage SCLC: A multicentre experience from Switzerland and the UK. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
20
|
Dawson L, Andrew E, Nehme Z, Bloom J, Cox S, Anderson D, Stephenson M, Lefkovits J, Taylor AJ, Kaye D, Guo Y, Smith K, Stub D. Temperature-related chest pain presentations and future projections with climate change. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Climate change has led to increased interest in studying adverse health effects relating to ambient temperatures. It is unclear whether incident chest pain is associated with non-optimal temperatures and how chest pain presentation rates might be affected by climate change.
Methods
The study included ambulance data of chest pain presentations in Melbourne, Australia from 1/1/2015 to 30/6/2019 with linkage to hospital and emergency discharge diagnosis data. A time series quasi-Poisson regression with a distributed lag nonlinear model was fitted to assess the temperature-chest pain presentation associations, after adjusting for season, day of the week and long-term trend. Future excess chest pain presentations associated with cold and heat were projected under six general circulation models under medium and high emission scenarios.
Results
In 206,789 chest pain presentations, mean (SD) age was 61.2 (18.9) years and 50.3% were female. Significant heat- and cold-related increased risk of chest pain presentations were observed for mean air temperatures above and below 20.8°C, respectively (Figure 1). Excess chest pain presentations related to heat were observed in all subgroups, but appeared to be attenuated for older patients (≥70 years) and patients of higher socioeconomic status (SES). We projected no significant change in net temperature-related chest pain presentations with climate change under medium- and high-emission scenarios, with increases in heat-related chest pain presentations offset by decreases in chest pain presentations related to cold temperatures.
Conclusions
Heat- and cold-exposure appear to increase risk of chest pain presentations, especially among younger patients and patients of lower SES. In Melbourne, Australia, chest pain presentations overall were not projected to increase with climate change, but increases in heat-related chest pain presentations highlight the importance of risk mitigation strategies to minimise adverse health impacts on hotter days.
Funding Acknowledgement
Type of funding sources: Public hospital(s). Main funding source(s): Alfred Health.
Collapse
Affiliation(s)
- L Dawson
- Royal Melbourne Hospital , Melbourne , Australia
| | - E Andrew
- Monash University , Melbourne , Australia
| | - Z Nehme
- Monash University , Melbourne , Australia
| | - J Bloom
- The Alfred Hospital , Melbourne , Australia
| | - S Cox
- Monash University , Melbourne , Australia
| | - D Anderson
- The Alfred Hospital , Melbourne , Australia
| | | | - J Lefkovits
- Royal Melbourne Hospital , Melbourne , Australia
| | - A J Taylor
- The Alfred Hospital , Melbourne , Australia
| | - D Kaye
- The Alfred Hospital , Melbourne , Australia
| | - Y Guo
- Monash University , Melbourne , Australia
| | - K Smith
- Monash University , Melbourne , Australia
| | - D Stub
- The Alfred Hospital , Melbourne , Australia
| |
Collapse
|
21
|
Dawson L, Andrew E, Stephenson M, Nehme Z, Bloom J, Cox S, Anderson D, Lefkovits J, Taylor AJ, Kaye D, Smith K, Stub D. Impact of ambulance off-load delays on mortality in patients with chest pain. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Ambulance off-load delays in transferring patient care to emergency departments (EDs) are increasingly common, but it is unclear whether clinical outcomes are impacted.
Methods
Population-based cohort study of ambulance attendances for non-traumatic chest pain transported to ED in Victoria, Australia (1/1/2015–30/6/2019) excluding patients transported to hospital with “lights and sirens” or triaged as ED category 1. Multivariable models were used to assess the relationship between ambulance off-load times and 30-day mortality and ambulance re-attendance for chest pain.
Results
The study included 213,544 ambulance attendances for chest pain (mean age 62 [SD 18] years; 51% female). Median ambulance off-load times increased across the study period from 21 minutes (interquartile range [IQR] 15–30) in 2015 to 24 minutes (IQR 17–37) in 2019. Patients were divided into tertiles according to off-load times with 69,247 patients included in tertile 1 (0–17 minutes), 73,109 patients in tertile 2 (18–28 minutes), and 71,188 patients in tertile 3 (>28 minutes). In multivariable models, ambulance off-load delays were associated with higher unadjusted and adjusted rates of 30-day mortality (1.57% tertile 3 vs. 1.29% tertile 1, adjusted risk difference 0.28% [95% CI 0.16% - 0.42%], p<0.001) and ambulance re-attendance for chest pain (9.89% tertile 3 vs. 8.59% tertile 1, adjusted risk difference 1.30% [95% CI 1.00% - 1.61%], p<0.001). Similarly, in analysis using off-load times as a continuous variable with restricted cubic splines, a non-linear increase in adjusted odds ratio for mortality was observed (Figure 1).
Conclusions
Delays in ambulance off-load times appear to be associated with increased mortality and ambulance re-attendance risk among chest pain cohorts. This study has important policy implications given the increasing frequency of off-load delays in many healthcare settings.
Funding Acknowledgement
Type of funding sources: Public hospital(s). Main funding source(s): Alfred health
Collapse
Affiliation(s)
- L Dawson
- Royal Melbourne Hospital , Melbourne , Australia
| | - E Andrew
- Monash University , Melbourne , Australia
| | | | - Z Nehme
- Monash University , Melbourne , Australia
| | - J Bloom
- The Alfred Hospital , Melbourne , Australia
| | - S Cox
- Monash University , Melbourne , Australia
| | - D Anderson
- The Alfred Hospital , Melbourne , Australia
| | - J Lefkovits
- Royal Melbourne Hospital , Melbourne , Australia
| | - A J Taylor
- The Alfred Hospital , Melbourne , Australia
| | - D Kaye
- The Alfred Hospital , Melbourne , Australia
| | - K Smith
- Monash University , Melbourne , Australia
| | - D Stub
- The Alfred Hospital , Melbourne , Australia
| |
Collapse
|
22
|
Navani RV, Dawson L, Andrew E, Nehme Z, Bloom J, Cox S, Anderson D, Stephenson M, Lefkovits J, Taylor A, Kaye D, Smith K, Stub D. Variation in health-care quality and outcomes according to time of chest pain presentation: a state-wide prospective cohort study. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Previous studies examining temporal variation in cardiovascular care have largely been limited to assessing weekend and after-hours effects whereby those presenting on the weekend or after-hours have a poorer outcome. However, emerging evidence suggests more complex patterns in patterns and outcomes may exist.
Purpose
We aimed to determine patterns of temporal variation in chest pain presentations and subsequent health-care quality and outcomes.
Methods
This was an observational, prospective-cohort study of adult patients aged 18 and over who were attended by emergency medical services for non-traumatic chest pain between 1 January 2015 and 30 June 2019 in Victoria, Australia. Major exclusion criteria included pre-hospital diagnosis of ST elevation myocardial infarction or an out of hospital cardiac arrest. The exposure variable was time of day and day of week stratified into 168 hourly time periods. The primary outcome measure was 30-day mortality.
Results
The study cohort comprised 196,365 ambulance attendances for acute non-traumatic chest pain; mean age 62.4 years (SD 18.3) and 99,497 (50.7%) females. Three temporal patterns were observed for chest pain presentations (Figure 1): (1) a diurnal pattern with a sharp increase in presentations from 8 am, peaking around midday, before decreasing into late evening with a nadir between 3–4 am, (2) a weekend effect where Saturday and Sunday had a relatively lower rate of presentations compared to during the week, and (3) a Monday – Sunday gradient where more presentations were likely earlier in the week, than later. Six patterns were identified across pre-hospital and hospital key performance indicators (KPI) (diurnal, in/after-hours, weekend effect, Monday – Sunday gradient, a peak period and morning vs afternoon/evening effect. Risk of 30-day mortality was associated with weekend presentation (OR 1.15, 95% CI 1.06–1.24, p=0.001) and morning presentation between midnight and midday (OR 1.17, 95% CI 1.09–1.25, p<0.001) (Figure 2).
Conclusion
Chest pain presentations, care quality and outcomes demonstrate complex temporal variation beyond the already established weekend and after-hours effect. Such relationships should be considered during resource allocation and quality improvement programs in order to improve treatment quality across all days and times of the week.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- R V Navani
- The Alfred Hospital, Department of Cardiology , Melbourne , Australia
| | - L Dawson
- The Alfred Hospital, Department of Cardiology , Melbourne , Australia
| | - E Andrew
- Ambulance Victoria , Melbourne , Australia
| | - Z Nehme
- Ambulance Victoria , Melbourne , Australia
| | - J Bloom
- The Alfred Hospital, Department of Cardiology , Melbourne , Australia
| | - S Cox
- Ambulance Victoria , Melbourne , Australia
| | - D Anderson
- Ambulance Victoria , Melbourne , Australia
| | | | - J Lefkovits
- Department of Epidemiology and Preventive Medicine, Monash University , Melbourne , Australia
| | - A Taylor
- The Alfred Hospital, Department of Cardiology , Melbourne , Australia
| | - D Kaye
- The Alfred Hospital, Department of Cardiology , Melbourne , Australia
| | - K Smith
- Ambulance Victoria , Melbourne , Australia
| | - D Stub
- The Alfred Hospital, Department of Cardiology , Melbourne , Australia
| |
Collapse
|
23
|
Ebner L, O O, Simon B, Lizarraga I, Smith J, Cox S. Pharmacokinetics of butorphanol following intravenous and intramuscular administration in donkeys: A preliminary study. Front Vet Sci 2022; 9:979794. [PMID: 36213418 PMCID: PMC9539103 DOI: 10.3389/fvets.2022.979794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2022] [Accepted: 08/11/2022] [Indexed: 11/22/2022] Open
Abstract
The pharmacokinetics of butorphanol after intravenous (IVB) and intramuscular (IMB) administration in donkeys were determined in this preliminary study. Healthy male gelded donkeys (n = 5), aged 6–12 years old, were administered 0.1 mg/kg butorphanol IV or IM in a randomized, crossover design. Blood samples were obtained at predetermined intervals for 24 h (IVB) and 48 h (IMB) after administration. Plasma butorphanol concentrations were determined by high performance liquid chromatography and pharmacokinetic parameters were calculated. Following IVB administration, mean (± SE) apparent volume of distribution, elimination half-life, total body clearance, and area under the plasma concentration time curve from time 0 to infinity (AUC0−∞) were 322 ± 50 mL/kg, 0.83 ± 0.318 h, 400 ± 114 mL/h/kg, 370 ± 131 h·ng/mL, respectively. After IMB administration, a maximum plasma drug concentration of 369 ± 190 ng/mL was reached at 0.48 ± 0.09 h. The IMB AUC0−∞ was 410 ± 60 h·ng/mL. Bioavailability of IMB was 133 ± 45%. The pharmacokinetics of butorphanol in healthy donkeys was characterized by faster elimination half-life compared to values from the equine literature.
Collapse
Affiliation(s)
- Lisa Ebner
- Department of Clinical Sciences, Ross University School of Veterinary Medicine, Basseterre, Saint Kitts and Nevis
- College of Veterinary Medicine, Lincoln Memorial University, Harrogate, TN, United States
- *Correspondence: Lisa Ebner
| | - Odette O
- Department of Clinical Sciences, Ross University School of Veterinary Medicine, Basseterre, Saint Kitts and Nevis
- SAGE Veterinary Centers, Dublin, CA, United States
| | - Bradley Simon
- Department of Clinical Sciences, Ross University School of Veterinary Medicine, Basseterre, Saint Kitts and Nevis
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, United States
| | - Ignacio Lizarraga
- Department of Biomedical Sciences, Ross University School of Veterinary Medicine, Basseterre, Saint Kitts and Nevis
| | - Joe Smith
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
- Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA, United States
| | - Sherry Cox
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| |
Collapse
|
24
|
Moliner L, Woodhouse L, Ahmed S, Bhagani S, Sevak P, Vijay A, Steele N, Gray HL, Robinson S, Davidson M, O'Brien M, Cox S, Powell C, Khalid T, T.R. Geldart, Hennah L, Newsom-Davis T, A. Denton, Blackhall F, Califano R. 1541P Real-world data of atezolizumab plus carboplatin-etoposide for patients with extensive stage SCLC: The UK experience. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
25
|
Stilz CR, Cox S, Bergman J, Gerhardt L, Singleton S, Harvill L, Souza MJ. Pharmacokinetics and Egg Residues of Oral Meloxicam in Bantam Cochin Chickens. J Avian Med Surg 2022; 36:140-144. [DOI: 10.1647/21-00023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
26
|
Strange K, Cox S, Patterson W, Lucas J, Turner T, Danby R, Hernandez D. Mesenchymal Stem/Stromal Cells: CHARACTERISATION OF HLA-G ISOFORM EXPRESSION IN UMBILICAL CORD – DERIVED MESENCHYMAL STROMAL CELLS AND THEIR POTENTIAL EFFECT ON IMMUNOMODULATION. Cytotherapy 2022. [DOI: 10.1016/s1465-3249(22)00189-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
27
|
Burlison C, Cox S, Smith J, Stokes J, Whittemore JC, DeBolt B. Pharmacokinetics of orally administered single‐dose ponazuril in cats. J Vet Pharmacol Ther 2022; 45:229-234. [PMID: 35307837 PMCID: PMC9311793 DOI: 10.1111/jvp.13047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2021] [Revised: 01/17/2022] [Accepted: 02/19/2022] [Indexed: 11/29/2022]
Abstract
Cats and kittens in animal shelters and catteries regularly suffer from severe gastrointestinal coccidiosis, which can be fatal, and there are no drugs labeled for feline coccidiosis in the United States. Ponazuril, a triazine‐class drug, is increasingly used at a dose of 50 mg/kg/d, orally, for three to five days in shelter environments for coccidiosis. A single oral dose of ponazuril paste 15% (Marquis®; Merial) at 50 mg/kg was administered to six healthy adult cats. Sample analysis was completed via high‐performance liquid chromatography. Plasma concentrations peaked at 7.49 ± 2.06 µg/ml at 14.67 ± 7.45 hr post‐administration. This study shows that ponazuril achieved a plasma concentration that inhibits growth of similar organisms after a single oral dose in cats. Further studies are necessary to optimize dosing for the treatment of clinical coccidiosis in cats.
Collapse
Affiliation(s)
- Catherine Burlison
- Department of Small Animal Clinical Sciences College of Veterinary Medicine The University of Tennessee Knoxville Tennessee USA
| | - Sherry Cox
- Department of Biomedical and Diagnostic Sciences College of Veterinary Medicine The University of Tennessee Knoxville Tennessee USA
| | - Joseph Smith
- Department of Large Animal Clinical Sciences College of Veterinary Medicine The University of Tennessee Knoxville Tennessee USA
| | - Jennifer Stokes
- Department of Small Animal Clinical Sciences College of Veterinary Medicine The University of Tennessee Knoxville Tennessee USA
| | | | - Becky DeBolt
- Department of Small Animal Clinical Sciences College of Veterinary Medicine The University of Tennessee Knoxville Tennessee USA
| |
Collapse
|
28
|
Gold JR, Grubb TL, Cox S, Malavasi L, Villarino NL. Pharmacokinetics and pharmacodynamics of repeat dosing of gabapentin in adult horses. J Vet Intern Med 2022; 36:792-797. [PMID: 35150014 PMCID: PMC8965223 DOI: 10.1111/jvim.16386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Revised: 01/29/2022] [Accepted: 01/31/2022] [Indexed: 11/26/2022] Open
Abstract
Background The repeated administration of high doses of gabapentin may provide better analgesia in horses than current clinical protocols. Hypothesis and Objectives Administration of gabapentin at 40 and 120 mg/kg PO q 12 h for 14 days will not alter serum biochemistry findings or cause adverse effects. Our objectives were to evaluate the effect of gabapentin on serum biochemistry, physical examination, and plasma pharmacokinetics of gabapentin. Animals Six healthy adult mares. Methods Horses received 40 and 120 mg/kg of gabapentin orally q 12 h for 14 days. Horses were examined and scored for ataxia and sedation daily. Serum biochemistry variables were analyzed before treatment and days 7 and 14 after gabapentin administration. Plasma disposition of gabapentin was evaluated after the first and last drug administration. Pharmacokinetic parameters were estimated using noncompartmental analysis. Results No changes occurred in physiologic or biochemical variables. Median (range) maximal plasma gabapentin concentrations (μg/mL) after the last dose (day 15) were 7.6 (6.2‐11) and 22 (14‐33) for 40 mg/kg and 120 mg/kg doses respectively. Maximal concentration of gabapentin was reached within 1 hour after drug administration. Repeated administration of gabapentin resulted in a median (range) area under the curve (AUC0‐12 hours) last/first dose ratio of 1.5 (1.00‐2.63) and 2.92 (1.4‐3.8) for the 40 and 120 mg/kg regimens, respectively. Conclusion and Clinical Importance Our results suggest that horses tolerate gabapentin up to 120 mg/kg PO q 12 h for 14 days. The analgesic effect of the dosage regimens evaluated in our study warrants further research.
Collapse
Affiliation(s)
- Jenifer R Gold
- Department of Veterinary Clinical Sciences, Washington State University, Pullman, WA, USA
| | - Tamera L Grubb
- Department of Veterinary Clinical Sciences, Washington State University, Pullman, WA, USA
| | - Sherry Cox
- Department of Biomedical and Diagnostic Sciences, University of Tennessee, Knoxville, Tennessee, USA
| | - Lais Malavasi
- Department of Veterinary Clinical Sciences, Washington State University, Pullman, WA, USA
| | - Nicholas L Villarino
- Department of Veterinary Clinical Sciences, Washington State University, Pullman, WA, USA
| |
Collapse
|
29
|
Camuglia A, Cole C, Boyne N, Hayman S, Cox S, Moore P, Lau J, Delacroix S, Williamson A, Duong M, Schwarz N, Montarello J, Worthley S. 30-Day Outcomes With the Portico™ Transcatheter Heart Valve: Insights From a Multi-Centre Australian Observational Study. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
30
|
Navani R, Dawson L, Andrew E, Nehme Z, Bloom J, Cox S, Anderson D, Stephenson M, Lefkovits J, Taylor A, Kaye D, Smith K, Stub D. Variation in Health-Care Quality and Outcomes According to Time of Chest Pain Presentation: A State-Wide Prospective Cohort Study. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
31
|
Aprile G, Dermedgoglou A, Jhaveri U, Singbal Y, Moore P, Kyranis S, Cox S. Safety and Feasibility of Day Case PCI in a Cardiac Catheter Laboratory in a Queensland Tertiary Hospital. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
32
|
Dawson L, Andrew E, Stephenson M, Nehme Z, Bloom J, Cox S, Anderson D, Lefkovits J, Taylor A, Kaye D, Smith K, Stub D. Impact of Ambulance Off-Load Delays on Mortality in Patients With Chest Pain. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
33
|
Chong A, Wahi S, Cox S, Nguyen S, Robinson J, Mew T, Singh S, Singbal Y. Echocardiographic vs Invasive Estimation of Left Atrial Pressure – Ongoing Search for the Holy Grail. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
34
|
Xiao X, Bloom J, Andrew E, Dawson L, Nehme Z, Stephenson M, Anderson D, Fernando H, Noaman S, Cox S, Chan W, Kaye D, Smith K, Stub D. Age as a Predictor of Clinical Outcomes and Determinant of Therapeutic Measures for Emergency Medical Services Treated Cardiogenic Shock. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
35
|
Cox S, Harvill L, Singleton S, Bergman JB, DeBolt B. The influence of storage time on ponazuril concentrations in feline plasma. PeerJ 2021; 9:e12516. [PMID: 34900432 PMCID: PMC8628618 DOI: 10.7717/peerj.12516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Accepted: 10/27/2021] [Indexed: 11/20/2022] Open
Abstract
Background The pharmacokinetics of ponazuril have been determined in several species; however, there is very little information on the stability of the drug after storage for long periods of time. This study was undertaken to determine the stability of ponazuril in plasma samples stored at -80 °C, which is the temperature most commonly used in the author's laboratory. Method Spiked plasma samples (0.3, 7.5, and 15 µg/mL) were stored at -80 °C for three months. Analysis occurred on the first day and then once a week for the following twelve weeks. The drug was extracted using a chloroform extraction and separated by high performance liquid chromatography using ultraviolet detection. Results There was no loss of drug for any concentration for the first four weeks of storage. There was an average loss of less than 5% from day 35 through day 70 and an average loss of 6% on day 77 and 84. The data suggest that ponazuril is stable for 4 weeks when stored at -80 °C and undergoes minimal loss in the remaining 8 weeks.
Collapse
Affiliation(s)
- Sherry Cox
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, United States of America
| | - Lainey Harvill
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, United States of America
| | - Sarah Singleton
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, United States of America
| | - Joan B Bergman
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, United States of America
| | - Becky DeBolt
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, United States of America
| |
Collapse
|
36
|
Videla R, Sommardahl C, Smith J, Schaefer DMW, Cox S. Pharmacokinetics of Orally Administered Prednisolone in Alpacas. Front Vet Sci 2021; 8:745890. [PMID: 34746285 PMCID: PMC8569471 DOI: 10.3389/fvets.2021.745890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2021] [Accepted: 09/06/2021] [Indexed: 11/15/2022] Open
Abstract
This study aimed to determine the pharmacokinetics of prednisolone following intravenous and oral administration in healthy adult alpacas. Healthy adult alpacas were given prednisolone (IV, n = 4), as well as orally (PO, n = 6). Prednisolone was administered IV once (1 mg/kg). Oral administration was once daily for 5 days (2 mg/kg). Each treatment was separated by a minimum 4 month washout period. Samples were collected at 0 (pre-administration), 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 4, 8, 12, and 24 h after IV administration, and at 0 (pre-administration), 0.25, 0.5, 0.75, 1, 2, 4, 8, 12, 24 after the first and 5th PO administration. Samples were also taken for serial complete blood count and biochemistry analysis. Prednisolone concentration was determined by high pressure liquid chromatography. Non-compartmental pharmacokinetic parameters were then determined. After IV administration clearance was 347 mL/kg/hr, elimination half-life was 2.98 h, and area under the curve was 2,940 h*ng/mL. After initial and fifth oral administration elimination half-life was 5.27 and 5.39 h; maximum concentration was 74 and 68 ng/mL; time to maximum concentration was 2.67 and 2.33 h; and area under the curve was 713 and 660 hr*ng/mL. Oral bioavailability was determined to be 13.7%. Packed cell volume, hemoglobin, and red blood cell counts were significantly decreased 5 days after the first PO administration, and serum glucose was significantly elevated 5 days after the first PO administration. In conclusion, serum concentrations of prednisolone after IV and PO administration appear to be similar to other veterinary species. Future research will be needed to determine the pharmacodynamics of prednisolone in alpacas.
Collapse
Affiliation(s)
- Ricardo Videla
- Department of Large Animal Clinical Sciences, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Carla Sommardahl
- Department of Large Animal Clinical Sciences, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Joe Smith
- Department of Large Animal Clinical Sciences, University of Tennessee, Knoxville, Knoxville, TN, United States.,Department of Biomedical Sciences, Iowa State University, Ames, IA, United States
| | - Deanna M W Schaefer
- Department of Biomedical and Diagnostic Sciences, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Sherry Cox
- Department of Biomedical and Diagnostic Sciences, University of Tennessee, Knoxville, Knoxville, TN, United States
| |
Collapse
|
37
|
Smith JS, Mochel JP, Soto-Gonzalez WM, Rahn RR, Fayne BN, Escher OG, Geletka AM, Harvill LE, Bergman JB, Cox S. Pharmacokinetics of Pantoprazole and Pantoprazole Sulfone in Goats After Intravenous Administration: A Preliminary Report. Front Vet Sci 2021; 8:744813. [PMID: 34631865 PMCID: PMC8492921 DOI: 10.3389/fvets.2021.744813] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Accepted: 08/26/2021] [Indexed: 12/29/2022] Open
Abstract
Background: Ruminant species are at risk of developing abomasal ulceration, but there is a lack of pharmacokinetic data for anti-ulcer therapies, such as the proton pump inhibitor pantoprazole, in goats. Objective: The primary study objective was to estimate the plasma pharmacokinetic parameters for pantoprazole in adult goats after intravenous administration. A secondary objective was to describe the pharmacokinetic parameters for the metabolite, pantoprazole sulfone, in goats. Methods: Pantoprazole was administered intravenously to six adult goats at a dose of 1 mg/kg. Plasma samples were collected over 36h and analyzed via reverse phase high performance liquid chromatography for determination of pantoprazole and pantoprazole sulfone concentrations. Pharmacokinetic parameters were determined by non-compartmental analysis. Results: Plasma clearance, elimination half-life, and volume of distribution of pantoprazole were estimated at 0.345 mL/kg/min, 0.7 h, and 0.9 L/kg, respectively following IV administration. The maximum concentration, elimination half-life and area under the curve of pantoprazole sulfone were estimated at 0.1 μg/mL, 0.8 h, and 0.2 hr*μg/mL, respectively. The global extraction ratio was estimated 0.00795 ± 0.00138. All animals had normal physical examinations after conclusion of the study. Conclusion: The reported plasma clearance for pantoprazole is lower than reported for foals, calves, and alpacas. The elimination half-life appears to be < that reported for foals and calves. Future pharmacodynamic studies are necessary for determination of the efficacy of pantoprazole on acid suppression in goats.
Collapse
Affiliation(s)
- Joe S Smith
- Systems Modeling and Reverse Translational Pharmacology, Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA, United States.,Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Jonathan P Mochel
- Systems Modeling and Reverse Translational Pharmacology, Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA, United States
| | - Windy M Soto-Gonzalez
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Rebecca R Rahn
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Bryanna N Fayne
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Olivia G Escher
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Anastasia M Geletka
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Lainey E Harvill
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Joan B Bergman
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| | - Sherry Cox
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States
| |
Collapse
|
38
|
Cox S, Harvill L, Singleton S, Bergman J, DeBolt B. Bioanalytical RP-HPLC method for the determination of ponazuril in plasma. Biomed Chromatogr 2021; 35:e5210. [PMID: 34216023 DOI: 10.1002/bmc.5210] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2021] [Revised: 06/14/2021] [Accepted: 06/29/2021] [Indexed: 11/05/2022]
Abstract
The goal of this investigation was to establish a reliable technique for the quantitation of ponazuril in limited sample volumes. Samples were extracted with chloroform and separation was achieved with a Symmetry RP18 column. Ultraviolet absorption was measured at 254 nm. A combination of 0.1% formic acid and acetonitrile (50:50) was used as the mobile phase. The calibration curve was linear from 0.1-25 μg/mL, with a lower limit of quantification of 0.1 μg/mL with a 100 μL sample. The precision and accuracy were well within the range set by the Food and Drug Administration and the recovery was over 95%. This technique was used to analyze ponazuril samples and found to be appropriate for pharmacokinetic studies.
Collapse
Affiliation(s)
- Sherry Cox
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, The University of Tennessee, Knoxville, TN, USA
| | - Lainey Harvill
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, The University of Tennessee, Knoxville, TN, USA
| | - Sarah Singleton
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, The University of Tennessee, Knoxville, TN, USA
| | - Joan Bergman
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, The University of Tennessee, Knoxville, TN, USA
| | - Becky DeBolt
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, The University of Tennessee, Knoxville, TN, USA
| |
Collapse
|
39
|
Bergman J, Harvill L, Hawkins S, Sladky K, Cox S. Determination of ceftazidime in plasma by RP-HPLC and ultraviolet detection. Biomed Chromatogr 2021; 35:e5104. [PMID: 33629742 DOI: 10.1002/bmc.5104] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2020] [Revised: 01/25/2021] [Accepted: 02/23/2021] [Indexed: 11/11/2022]
Abstract
A simple high-performance liquid chromatography method for the determination of ceftazidime in plasma has been developed. Using an ultrafiltration technique samples were separated by reverse-phase high-performance liquid chromatography on a Symmetry C18 4.6 × 250 mm column (5.0 μm) and ultraviolet absorbance was measured at 260 nm. The mobile phase was a mixture of 10 mm potassium phosphate monobasic pH 2.5 with phosphoric acid and acetonitrile (90:10). The standard curve ranged from 0.1 to 100 μg/ml. Intra- and inter-assay variability for ceftazidime was <12%, and the average recovery was 89%. The lower limit of quantification was 0.1 μg/ml. This method has been used successfully to analyze frog plasma samples at this institution and it could be applied to other small volume samples in a clinical or research setting.
Collapse
Affiliation(s)
- Joan Bergman
- College of Veterinary Medicine, Department of Biomedical and Diagnostic Sciences, The University of Tennessee, Knoxville, TN, USA
| | - Lainey Harvill
- College of Veterinary Medicine, Department of Biomedical and Diagnostic Sciences, The University of Tennessee, Knoxville, TN, USA
| | - Shawna Hawkins
- Department of Surgical Sciences, School of Veterinary Medicine, The University of Wisconsin, Madison, WI, USA
| | - Kurt Sladky
- Department of Surgical Sciences, School of Veterinary Medicine, The University of Wisconsin, Madison, WI, USA
| | - Sherry Cox
- College of Veterinary Medicine, Department of Biomedical and Diagnostic Sciences, The University of Tennessee, Knoxville, TN, USA
| |
Collapse
|
40
|
Noel-Storr A, Dooley G, Wisniewski S, Glanville J, Thomas J, Cox S, Featherstone R, Foxlee R. Cochrane Centralised Search Service showed high sensitivity identifying randomized controlled trials: A retrospective analysis. J Clin Epidemiol 2020; 127:142-150. [DOI: 10.1016/j.jclinepi.2020.08.008] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2020] [Revised: 07/01/2020] [Accepted: 08/11/2020] [Indexed: 12/26/2022]
|
41
|
Kahan J, Carrington R, Cox S, Lewis G, Gwynne S. PD-0548: Quantitative Analysis of SCOPE 2 Trial 4DCT pre-accrual benchmark cases. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00570-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
42
|
Graves MT, Schneider L, Cox S, Caldwell M, Krawczel P, Lee A, Lear A. Evaluation of the pharmacokinetics and efficacy of transdermal flunixin for pain mitigation following castration in goats. Transl Anim Sci 2020; 4:txaa198. [PMID: 33324963 PMCID: PMC7724925 DOI: 10.1093/tas/txaa198] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2020] [Accepted: 10/27/2020] [Indexed: 11/14/2022] Open
Abstract
The mitigation of pain associated with common management procedures is a rising concern among veterinarians, producers and consumers. Nonsteroidal anti-inflammatory drugs are vital compounds for this purpose due to their cost, convenience, and efficacy. A transdermal formulation of flunixin meglumine (FM) was approved for the treatment of pain in cattle; however, the efficacy has yet to be determined for small ruminants. The current study had two aims: 1) to determine the pharmacokinetics of transdermal flunixin meglumine (TD FM) in bucklings and 2) to evaluate pain mitigation by TD FM following castration. To evaluate pharmacokinetics, 12 male goats (mean age = 6 mo) received 2.2 mg/kg of FM IV (n = 6) or 3.3 mg/kg TD FM (n = 6). Plasma FM concentrations were measured. The mean Cmax, Tmax, and harmonic mean half-life for TD FM were 1.09 ± 0.65 μg/mL, 5.50 ± 2.95 h, and 7.16 ± 2.06 h, respectively. To evaluate the efficacy of pain mitigation, 18 goats were randomly assigned to three treatment groups: 1) TD FM and castration (FM CAST) (n = 6); 2) transdermal placebo and castration (PL CAST) (n = 6); and 3) TD FM and sham castration (SHAM) (n = 6). Plasma samples were collected at 0, 12, 24, 36, 48, 72, and 96 h to assess cortisol and prostaglandin E2 (PGE2). Daily dry matter intake (DMI) was recorded and body weight was measured at the beginning and end of the study. Thermography (IRT) images of the scrotum, as well as heart rate (HR), respiratory rate (RR), and rectal temperature, were taken twice daily. Separate mixed analysis of variance models were used to test the effects of treatment, time, and their interaction on mean body temperature, IRT, HR, and RR. Autoregressive covariance structure was utilized to account for repeated measures and individual goat DMI prior to the study was added as a covariate. There were no differences in vital parameters, IRT measurements, cortisol, or PGE2 in animals receiving either TD FM or placebo following castration (P > 0.05). DMI had a treatment by hour interaction and was significantly higher in FM CAST and SHAM groups than the PL CAST group (P = 0.04). Goats in the SHAM group gained weight throughout the study, whereas goats in all other groups lost weight (P = 0.02). Results indicate that TD FM may mitigate pain as demonstrated by increased DMI; however, a single dose may not be sufficient to reduce physiological indicators of pain associated with castration in goats.
Collapse
Affiliation(s)
- Meggan T Graves
- Large Animal Clinical Sciences, University of Tennessee College of Veterinary Medicine, Knoxville, TN
| | - Liesel Schneider
- Department of Animal Science, University of Tennessee Institute of Agriculture, Knoxville, TN
| | - Sherry Cox
- Biomedical and Diagnostic Sciences, University of Tennessee College of Veterinary Medicine, Knoxville, TN
| | - Marc Caldwell
- Large Animal Clinical Sciences, University of Tennessee College of Veterinary Medicine, Knoxville, TN
| | - Peter Krawczel
- Department of Animal Science, University of Tennessee Institute of Agriculture, Knoxville, TN.,Department of Agricultural Sciences and Animal Science, University of Helsinki, Helsinki, Finland.,Department of Production Animal Medicine at the Research Centre for Animal Welfare, University of Helsinki, Helsinki, Finland.,Helsinki One Health (HOH), University of Helsinki, Helsinki, Finland
| | - Amanda Lee
- Department of Animal Science, University of Tennessee Institute of Agriculture, Knoxville, TN
| | - Andrea Lear
- Large Animal Clinical Sciences, University of Tennessee College of Veterinary Medicine, Knoxville, TN
| |
Collapse
|
43
|
Przedlacka A, Cox S, Tekkis P, Bello F, Kontovounisios C. Rectal 3D MRI modelling for benign and malignant disease. Br J Surg 2020; 107:e561-e562. [PMID: 32841363 DOI: 10.1002/bjs.11858] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Received: 02/10/2020] [Revised: 05/04/2020] [Accepted: 06/05/2020] [Indexed: 11/09/2022]
Affiliation(s)
- A Przedlacka
- Department of Surgery and Cancer, Imperial College London
| | - S Cox
- Department of Surgery and Cancer, Imperial College London
| | - P Tekkis
- Department of Surgery and Cancer, Imperial College London
| | - F Bello
- Imperial College London, Centre for Engagement and Simulation Science
| | | |
Collapse
|
44
|
Cox S, Bergman J, Allender MC, Beckmen K, Lance W. Determination of Thiafentanil in Plasma Using LC-MS. J Chromatogr Sci 2020; 58:1-4. [PMID: 31813994 DOI: 10.1093/chromsci/bmz098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Revised: 02/01/2019] [Accepted: 10/21/2019] [Indexed: 11/13/2022]
Abstract
A new method of analysis has been developed and validated for the determination of thiafentanil in plasma. After protein precipitation, samples were separated on an XBridge BEH C18 column and quantified using mass spectrometry. The mobile phase was a mixture of water with 0.1% formic acid and acetonitrile with 0.1% formic acid (90:10). The standard curve ranged from 0.1 to 25 ng/mL. Intra- and Inter-assay variability for thiafentanil was less than 10%, and the average recovery was greater than 95%. The lower limit of quantification was 0.1 ng/mL. This is the first validated method for thiafentanil analysis in plasma.
Collapse
Affiliation(s)
- Sherry Cox
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, 2407 River Drive, Knoxville, TN, USA
| | - Joan Bergman
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, 2407 River Drive, Knoxville, TN, USA
| | - Matthew C Allender
- Wildlife Epidemiology Laboratory, Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana IL, USA
| | - Kimberlee Beckmen
- Wildlife Health and Disease Surveillance Program, Division of Wildlife Conservation, Alaska Department of Fish and Game, 1300 College Road, Fairbanks AK, USA
| | - William Lance
- Wildlife Pharmaceuticals Inc., 1230 West Ash, Windsor, CO, USA
| |
Collapse
|
45
|
Cox S, Sommardahl C, Fortner C, Davis R, Bergman J, Doherty T. Determination of grapiprant plasma and urine concentrations in horses. Vet Anaesth Analg 2020; 47:705-709. [PMID: 32439238 DOI: 10.1016/j.vaa.2020.04.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2019] [Revised: 04/09/2020] [Accepted: 04/12/2020] [Indexed: 01/06/2023]
Abstract
OBJECTIVE Non-steroidal anti-inflammatory drugs are inhibitors of cyclooxygenase (COX) in tissues and used as therapeutic agents in different species. Grapiprant, a member of the piprant class of compounds, antagonizes prostaglandin receptors. It is a highly selective EP4 prostaglandin E2 receptor inhibitor, thereby limiting the potential for adverse effects caused by wider COX inhibition. The objectives of this study were to determine if the approved canine dose would result in measurable concentrations in horses, and to validate a chromatographic method of analysis for grapiprant in urine and plasma. STUDY DESIGN Experimental study. ANIMALS A total of six healthy, adult mixed-breed mares weighing 502 ± 66 (397-600) kg and aged 14.8 ± 5.3 (6-21) years. METHODS Mares were administered one dose of 2 mg kg-1 grapiprant via nasogastric tube. Blood and urine samples were collected prior to and up to 48 hours after drug administration. Drug concentrations were measured using high-performance liquid chromatography. RESULTS Grapiprant plasma concentrations ranged from 71 to 149 ng mL-1 with the mean peak concentration (106 ng mL-1) occurring at 30 minutes. Concentrations were below the lower limit of quantification (50 ng mL-1) in four of six horses at 1 hour and in all six horses by 2 hours after drug administration. Grapiprant urine concentrations ranged from 40 to 4077 ng mL-1 and were still detectable at 48 hours after administration. CONCLUSIONS AND CLINICAL RELEVANCE Currently, there are no published studies looking at the pharmacodynamics of grapiprant in horses. The effective concentration needed to control pain in dogs ranges 114-164 ng mL-1. Oral administration of grapiprant (2 mg kg-1) in horses did not achieve those concentrations. The dose was well tolerated; therefore, studies with larger doses could be conducted.
Collapse
Affiliation(s)
- Sherry Cox
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, USA.
| | - Carla Sommardahl
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, USA
| | - Chelsey Fortner
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, USA
| | - Rebecca Davis
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, USA
| | - Joan Bergman
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, USA
| | - Tom Doherty
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, USA
| |
Collapse
|
46
|
Gold JR, Grubb TL, Green S, Cox S, Villarino NF. Plasma disposition of gabapentin after the intragastric administration of escalating doses to adult horses. J Vet Intern Med 2020; 34:933-940. [PMID: 32034928 PMCID: PMC7096665 DOI: 10.1111/jvim.15724] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2019] [Accepted: 01/30/2020] [Indexed: 11/30/2022] Open
Abstract
Background In humans, gabapentin an analgesic, undergoes non‐proportional pharmacokinetics which can alter efficacy. No information exists on the pharmacokinetics of dosages >20 mg/kg, escalating dosages or dose proportionality of gabapentin in horses. Hypothesis and Objectives Gabapentin exposure in plasma would not increase proportionally relative to the dose in horses receiving dosages ≥20 mg/kg. To assess the plasma pharmacokinetics of gabapentin after nasogastric administration of gabapentin at dosages of 10 to 160 mg/kg in adult horses. Animals Nine clinically healthy adult Arabian and Quarter Horses. Methods In a randomized blinded trial, gabapentin was administered by nasogastric intubation to horses at 10, 20 mg/kg (n = 3) and 60, 80, 120, 160 mg/kg (n = 6). Plasma was collected before and at regular times over 64 hours after administration of gabapentin. Gabapentin was quantified using a validated chromatographic method. Dose proportionality was estimated using a power model. Pharmacokinetic parameters were estimated using compartmental pharmacokinetic analysis. Results Plasma pharmacokinetics parameters of gabapentin were estimated after nasogastric administration at dosages of 10 to 160 mg/kg. Gabapentin plasma concentration increased with dose increments. However, the area under the concentration curve from zero to infinity and maximal plasma concentration did not increase proportionally relative to the dose in horses. Conclusions and Clinical Importance Gabapentin exposure in plasma is not proportional relative to the dose in horses receiving nasogastric dosages of 10 to 160 mg/kg.
Collapse
Affiliation(s)
- Jenifer R Gold
- Department of Veterinary Clinical Sciences, Washington State University, Pullman, Washington
| | - Tamara L Grubb
- Department of Veterinary Clinical Sciences, Washington State University, Pullman, Washington
| | - Stephen Green
- Department of Veterinary Clinical Sciences, Washington State University, Pullman, Washington
| | - Sherry Cox
- Department of Biomedical and Diagnostic Sciences, University of Tennessee, Knoxville, Tennessee
| | - Nicolas F Villarino
- Department of Veterinary Clinical Sciences, Washington State University, Pullman, Washington
| |
Collapse
|
47
|
Boyle S, McCallum C, Cox S, Vollbon W, Chong A, Wahi S. 354 Incidence and Implication of Persistently Positive Agitated Saline Contrast Studies (ASCS) at 6 Months Post-transcatheter Patent Foramen Ovale (PFO) Closure - Is the Juice Worth the Squeeze? Heart Lung Circ 2020. [DOI: 10.1016/j.hlc.2020.09.361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
48
|
Yeong C, Conners G, Cox S, Garrahy P, Kyranis S, Lim R, McCann A, Moore P, Singbal Y, Camuglia A. 902 Time to First Device Time in ST Elevation Myocardial Infarction (STEMI) at a High-Volume STEMI Centre Stratified by Access Site Approach. Heart Lung Circ 2020. [DOI: 10.1016/j.hlc.2020.09.909] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
49
|
Wahl K, Lisonek M, Smith K, Yong P, Cox S. 117 Listening to Women with Endometriosis-associated Sexual Pain: Interim Findings from EndoViews. J Sex Med 2019. [DOI: 10.1016/j.jsxm.2019.03.555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
50
|
Cox S, Miles E, Staffurth J, Gwynne S. PO-1105 Impact of deviations in target volume delineation - time for a new RTQA approach? Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31525-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|